Research on discovering and developing new drugs. Covers structure-revealing tools, eye-disease mechanisms, protein screening, and once-daily oral medicines.
Professor John Bower joins the University of Bath as the new Raymond Schinazi and Family Chair of Science, bringing expertise in synthetic and medicinal chemistry to enhance the university's research capabilities. He aims to translate fundamental research into real-world impact, supporting the development of new sustainable processes f...
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
The University of Kansas has received $5.8 million in NIH funding to further its Chemical Biology of Infectious Disease center, which aims to develop targeted treatments for antibiotic-resistant pathogens. The center's collaborative approach will focus on protecting the beneficial microbiome while defeating resistance mechanisms.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
New York University researchers have trained an AI model to predict stable tautomers in drug-like molecules, addressing a challenge in molecular design. The model, released as an open-source tool, can analyze large molecular libraries and identify correct tautomer assignments.
A UCF researcher and her team used AI to screen existing FDA-approved drugs for potential treatments of schwannoma tumors in children with Neurofibromatosis type 2. The research identified 10 promising candidates, with the most favorable targets stopping tumor cell growth by impacting different cellular mechanisms.
The University of Melbourne has joined the Structural Genomics Consortium to develop AI-powered tools for drug discovery, targeting rare diseases. The new SGC-Melbourne facility will generate large-scale datasets on protein-molecule interactions, enabling the creation of high-quality data needed for AI to predict new molecular tools.
A virtual biotech company powered by AI agents has made groundbreaking discoveries in drug discovery, including a biological signal that predicts which drug candidates are more likely to succeed. The company has also designed a cancer therapy that was later independently built by a major pharmaceutical company.
The conference will explore next-generation biologics and immunotherapies, targeted protein modulation, and emerging therapies for oncogenic drivers. Experts will discuss the role of artificial intelligence in accelerating therapeutic development.
A new treatment option has been approved in Japan for patients with PFIC types 1 and 2, a rare genetic liver disorder. The treatment, which targets the mechanism behind bile movement, may help slow down liver damage and improve quality of life for children and adults with these disorders.
Researchers identified a novel glycosyltransferase enzyme, PamUGT, from American pokeweed, which can decorate five major classes of natural products. The enzyme shows remarkable promiscuity, using multiple UDP-sugars to glycosylate diverse substrates.
Researchers developed a flexible metal–organic framework, APF-40, to analyze large pharmaceutical molecules with complex structures. The framework enables the determination of structures from microgram-scale samples, aiding drug discovery and natural products research.
Researchers discovered PECAM-dependent mechanism for immune cell traffic in the retina, identifying neutrophils as proresolving mediators. Targeting PECAM controlled white blood cell traffic, leading to improved clinical outcomes in uveitis model.
A new high-throughput tool developed by Stanford University scientists can detect small changes in protein levels within cells, enabling faster and more efficient drug discovery. By amplifying these changes, researchers can identify potential therapeutic targets for diseases like cancer, potentially leading to breakthroughs in treatment.
A clinical trial found that AZD5462, a new oral medication, was well-tolerated and improved cardiac remodeling and blood flow in patients with heart failure. The results suggest that AZD5462 may be a promising treatment option for patients with chronic heart failure.
The 21st Century Cures Act led to a significant decrease in the number of studies relied on for FDA approvals, from 3.41 to 1.39, between 2016 and 2024. This shift has raised concerns about the safety and effectiveness of new therapeutics.
A research team created an ultrathin artificial lung that reproduces the movement of alveoli, air sacs inside the lung, and demonstrates the response to influenza virus. The lung operated stably through 240,000 breaths and showed promise for studying lung disease and drug responses.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Researchers found that dexamethasone reduces infection-driven macrophage metabolic activity and lowers inflammatory signals, preserving the immune system's ability to control the infection. This study suggests a new approach for managing nontuberculous mycobacterial disease.
The new integrations provide enterprise AI agents direct access to live, structured research data from Dimensions' 430M+ interconnected records. This allows for AI-assisted analytics across one of the world's most comprehensive linked views of global research activity.
Researchers have found a new compound that promotes joint health and reduces inflammation-related genes in a model of osteoarthritis. The drug, M04, has shown promise as an innovative OA therapy by slowing down the disease process, giving people more years of pain-free living.
Tirzepatide has been shown to reduce the risk of heart attacks and hospitalizations due to infections in people with type 2 diabetes and obesity. The study found a relative risk reduction of about one-third, corresponding to a 36% reduced risk of infection-related hospitalization.
Researchers have uncovered a key mechanism explaining how allergic inflammation in the skin can progress to a body-wide allergic response. IL-13 acts on dendritic cells, enhancing their ability to present allergens and promoting immune responses that produce antibodies.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
A new study reveals that photoreceptors possess an internal recycling system that removes damaged proteins and maintains cellular health. This discovery has important implications for inherited retinal diseases and raises questions about the safety of certain drugs in clinical testing.
Researchers at the University of Manchester have developed a new family of antifungal agents that are more potent and less toxic than existing treatments. The compounds, which were discovered through genome mining, showed increased antifungal activity and improved solubility compared to existing drugs.
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
A new peptide derived from cone snail venom has been shown to significantly reduce inflammation-induced pain in an animal model. The peptide specifically inhibits the noradrenaline transporter, supporting the body's own pain-inhibiting mechanisms.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
OYE Therapeutics announced positive Phase 1 results for OYE-101, a proprietary intravenous caffeine formulation. The study demonstrated the safety and tolerability of OYE-101 in healthy adult volunteers, supporting its planned development as a treatment to support emergence from general anesthesia and deep sedation.
Researchers developed a new method using blue LED lights and commercial chemical building blocks to modify two carbon atoms in a single reaction, increasing the complexity of molecules quickly. This approach could lead to faster production of complex drugs with specific properties.
Deep learning models accelerate drug design, predict chemical interactions, and engineer stable candidates. AI-powered simulations optimize dosimetry, predicting biodistribution and generating patient-specific digital twins for individualized treatment planning.
A novel therapy targeting the bone marrow microenvironment is shown to accelerate recovery and promote hematopoietic regeneration after injury. Pharmacological activation of YAP/TAZ improves BM niche recovery, enhancing engraftment and white blood cell recovery following HSCT.
Macrophages are critical drivers of chronic allograft failure, with emerging strategies targeting key macrophage signaling pathways providing an important conceptual shift. Targeted therapies, such as inhibiting the purinergic pathway and mTOR/NF-κB pathway, show promise in preventing chronic rejection.
A Wisconsin lab advance has developed a way to remove liquid chromatography from peptide mapping, an essential test for determining a candidate drug's stability. This technique accelerates the process by 100-fold, allowing companies to analyze massive data influx instantly and reducing costs.
Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.
Researchers have identified a promising drug to treat neurodegenerative conditions, including Alzheimer's disease and traumatic brain injury. The study found that inhibition of an enzyme called 15-PGDH was potently neuroprotective by restraining the production of reactive oxygen species that damage the brain.
A new PNAS special feature showcases the critical role of behavioral and decision sciences in U.S. governance, highlighting how psychological and economic research protect public health, consumer rights, and finances across federal agencies. The research demonstrates how 'invisible' scientific frameworks streamline medical drug reviews...
Researchers at the University of Warwick and Monash University have uncovered a molecular basis for combinatorial biosynthesis, a strategy to create multiple versions of powerful cancer therapies. By understanding how bacterial enzymes interact, they can design new therapies with improved potency and selectivity.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A POSTECH research team has created an automated, modular system for assembling reconstituted cell-free systems, significantly reducing costs by 95% and preparation time to 2 days. This innovation enables the customization of individual components, paving the way for improved biologically engineered high-value therapeutics.
Researchers found that over-the-counter probiotics contain only 36 unique species of bacteria, with most common species being forms of Lactobacillus. The analysis suggests a lack of consistency in the combination of species used to support gut health and vaginal health claims.
A comprehensive analysis of 173,303 Pakistani genomes reveals the presence of 34,000 people with complete loss of function of at least one gene, known as 'human knockouts'. This study provides valuable information needed to develop new treatments for human diseases and sheds light on why drugs developed in mice often fail in humans.
Researchers at the University of Houston have discovered adding salt can help release therapeutic material from endosomes, improving delivery efficiency for mRNA vaccines and gene therapies. The simple strategy overcomes a major obstacle in gene medicine, potentially making these therapies more efficient and accessible worldwide.
Universities and hospitals conduct substantial numbers of late-stage clinical trials to repurpose generic drugs at reduced costs. This research has huge potential to provide society with affordable treatments for various conditions.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Researchers found that temperature and calcium levels inside cells can dramatically impact how drugs interact with their targets. This discovery could lead to smarter medicine design and more effective treatments.
Researchers discovered a previously unknown binding site in a cancer-related protein that could lead to more precise cancer drugs. The study reveals the power and limitations of AI tools for drug discovery, showing that even small chemical changes can dramatically alter how molecules bind to proteins.
Scientists create a moiré metasurface to map right- and left-handed regions in materials, visualizing chirality as two-dimensional images. The new approach resolves chirality distributions with a resolution of approximately 100 μm.
Researchers developed a miniaturized human intestine model to study EV-A71 infection, revealing the virus's ability to evade the immune system and persist for extended periods. The model showed long-term viral replication without triggering a strong immune response.
Researchers at EPFL have discovered a way to generate and screen large libraries of synthetic cyclic peptides that can both enter cells and block disease-related protein interactions. This breakthrough could broaden access to previously difficult targets for drug development, enabling the creation of orally available peptide drugs.
Two projects, BOOST-HP and BIONIC, use machine learning to analyze large datasets of medication exposure and outcomes. The findings highlight the need for more data and cautious design of machine learning models to accurately assess potential links between medications and pregnant women.
Researchers identified a vitamin K-dependent GAS6 pathway that controls osteoclast maturation and bone resorption in mice. Osteoblasts use Vitamin K signals to regulate osteoclast fusion via the GAS6 pathway.
Researchers at UW Medicine Institute for Protein Design and Skape Bio used AI methods to create on-demand molecules that can toggle GPCRs. The approach enables precise control of GPCR signaling in cells, offering new insights into bodily functions and potential medicines for diseases.
Researchers used wastewater surveillance to detect drug-resistant Candida auris strains up to five months before patients showed symptoms, opening a new frontier for hospitals. The study found higher detection rates and concentrations of the pathogen in hospital wastewater compared to community-scale treatment plants.